semaglutide and mcas Effects of on the expression of C-raf, ERK, caspase-3 Mast Cell Activation Syndrome (MCAS)

The answer depends on your diet, labs, medications, age, and provider recommendations

The result is a more youthful appearance and less sagging

GLP-1 medications are initiated at low doses and gradually increased over several weeks to minimise gastrointestinal side effects

In the TECOS trial treatment sitagliptin also reduced the urinary albumin to creatinine ratio with no effect on eGFR (273)

They can assess how GLP-1 medications interact with existing conditions like diabetes or thyroid disorders, making them valuable partners for complex cases

Healthcare is about trust and I believe tech can enhance this trust or break it